Nanoparticle-aptamer bioconjugates for cancer targeting.
The combination of targeted drug delivery and controlled-release technology may pave the road for more effective yet safer chemotherapeutic options for cancer therapy. Drug-encapsulated polymeric nanoparticle-aptamer bioconjugates represent an emerging technology that can facilitate the delivery of chemotherapeutics to primary and metastatic tumours. Aptamers are short nucleic acid molecules with binding properties and biochemical characteristics that may make them suitable for use as targeting molecules. The goal of this review is to summarise the key components that are required for creating effective cancer targeting nanoparticle-aptamer bioconjugates. The field of controlled release and the structure and properties of aptamers, as well as the criteria for constructing effective conjugates, will be discussed.
Farokhzad
Omid C
OC
Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital and Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA. ofarokhzad@partners.org
Karp
Jeffrey M
JM
Langer
Robert
R
D000818:Animals; D052157:Aptamers, Nucleotide / Q000737:chemistry / Q000302:isolation & purification / Q000627:therapeutic use*; D003692:Delayed-Action Preparations / Q000737:chemistry / Q000627:therapeutic use; D016503:Drug Delivery Systems / Q000379:methods*; D006801:Humans; D049329:Nanostructures / Q000737:chemistry*; D009369:Neoplasms / Q000188:drug therapy*; D052156:SELEX Aptamer Technique; D013499:Surface Properties
D052157:Aptamers, Nucleotide; D003692:Delayed-Action Preparations